Q.Suite positioned as improvement in cancer treatment assessment.
GE Healthcare today officially introduced Q.Suite, tools designed to improve PET for oncology treatment assessment by creating more consistent readings.
Thanks to its ability to indicate metabolic change, PET can reveal whether a given oncology treatment is working or not, even before a physical change in tumor size can show up in CT or MR images, according to Vivek Bhatt, general manager for PET at GE Healthcare.
But Standardized Uptake Value (SUV) readings have to be consistent for physicians to rely on data showing a change from the baseline. Variation control is needed.
Q.Suite offers stability through:
• Q.Freeze - Designed to be combine the quantitative benefits of 4D phase-matched PET/CT imaging into a single static image, eliminating motion, Q.Freeze is 510(k) pending at the FDA and is not available for sale in the United States.
• Q.Static - Adds basic motion correction techniques, reducing organ motion effects. The tool is meant to automatically isolate data when organs are in a low-motion state. The result is a single image series with reduced blurring from organ motion.
• Q.AC - An algorithm is designed to reduce potential variance in attenuation correction measurements, helping ensure that the attenuation coefficients used in image reconstruction are accurate.
• Q.Check - Establishes a link between the console and workstation to ensure that patient and exam data required for quantitative imaging is saved in the patient file before the exam is finished.
• Q.Core - Manages both PET acquisition and reconstruction processing at faster speeds.
• PET VCAR - Provides access to quantitative information, managing multiple lesions and multiple patient exams over time. PET VCAR now supports PERCIST.
GE also announced its new Discover PET/CT 710, capable of 128-slice imaging, and stressed its research on developing a fully integrated PET/MR.
Can MRI-Based AI Bolster Biopsy Decision-Making in PI-RADS 3 Cases?
December 9th 2024In patients with PI-RADS 3 lesion assessments, the combination of AI and prostate-specific antigen density (PSAD) level achieved a 78 percent sensitivity and 93 percent negative predictive value for clinically significant prostate cancer (csPCa), according to research presented at the Radiological Society of North American (RSNA) conference.
The Reading Room: Artificial Intelligence: What RSNA 2020 Offered, and What 2021 Could Bring
December 5th 2020Nina Kottler, M.D., chief medical officer of AI at Radiology Partners, discusses, during RSNA 2020, what new developments the annual meeting provided about these technologies, sessions to access, and what to expect in the coming year.
RSNA 2020: Addressing Healthcare Disparities and Access to Care
December 4th 2020Rich Heller, M.D., with Radiology Partners, and Lucy Spalluto, M.D., with Vanderbilt University School of Medicine, discuss the highlights of their RSNA 2020 session on health disparities, focusing on the underlying factors and challenges radiologists face to providing greater access to care.
New Interventional Radiology Research Shows Merits of Genicular Artery Embolization for Knee OA
December 3rd 2024In a cohort of over 160 patients with knee osteoarthritis (OA), including grade 4 in nearly half of the cases, genicular artery embolization led to an 87 percent improvement in the quality of life index, according to research presented at the
Siemens Healthineers Debuts New Photon-Counting CT Systems at RSNA
December 2nd 2024Debuting at the Radiological Society of North American (RSNA) conference, the new photon-counting computed tomography (PPCT) scanners Naeotom Alpha.Pro and Naeotom Alpha.Prime reportedly combine rapid scan times with high-resolution precision.